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Stereotactic body radiotherapy (SBRT) has become the 
guideline recommended treatment for patients with stage 
I non-small cell lung cancer (NSCLC), who are medically 
inoperable due to their comorbidities (1). In historical 
comparisons, SBRT has achieved substantially improved 
local tumor control compared to conventional radiotherapy, 
which has translated into improved overall survival (OS) (2). 
Additionally, SBRT is safe and effective even in highly fragile 
patient populations suffering from serve comorbidities or 
being at very advanced age.
The promising results of SBRT in medically inoperable 
patients have prompted the evaluation of SBRT in healthy 
patients, where lobectomy and systematic hilar and 
mediastinal lymph node dissection is the standard of care. 
Ideally, randomized controlled trials would have answered 
the question about the value of SBRT compared to surgical 
lobectomy. Three randomized controlled trials comparing 
SBRT and lobectomy have been started (ROSEL; STARS; 
RTOG 1021/ACOSOG Z4099) but closed early due 
to very poor patient accrual. Further trials comparing 
SBRT with surgical resection are planned or are already 
open (SABRTooth; STABLE-MATES; VALOR) and 
more advanced techniques of randomization and patient 
information will be used in these trials. However, we will 
remain without highest level of evidence for several years.
Knowns
Several sources of evidence are today available to guide 
the current discussion of SBRT compared to lobectomy. 
All are below the evidence level of randomized controlled 
trials, all have their specific methodological limitations and 
interpretation of all these studies needs to consider these 
limitations.
Data of two randomized trials (ROSEL & STARS) have 
been pooled and a joint analysis has been performed (3). 
Only 58 patients in total were available for analysis, which is a 
major limitation of this study. Median age of the patients was 
67 years without differences between the two cohorts. After 
sufficient follow-up of >40 months, 3 years OS was 95% and 
79% in the SBRT and surgical group (P=0.037), respectively. 
No differences in local recurrence and recurrence free 
survival were observed. Grade 3 & 4 complications were 
observed in 44% of the patients after lobectomy whereas only 
10% of the patients developed grade 3 toxicity after SBRT. 
Only 22 patients were randomized in the ROSEL trial and 
an exploratory analysis described patient reported outcome. 
Overall, quality of life was consistently better after SBRT 
compared to lobectomy but reached statistical significance 
only in global health status (4).
Only one prospective single-arm phase II trial using 
SBRT in medical operable patients has been fully reported, 
yet. The JCOG0403 study included patients with cT1cN0 
NSCLC and was open for medically operable and medically 
inoperable patients (5): the status operable was defined as 
an expected postoperative forced expiratory volume 1.0 
>800 mL; PaO2 >65 torr (under room air) and no severe 
cardiac morbidity and no severe diabetes mellitus. Sixty 
four of 164 eligible patients were medically operable and 
their median age was 79 years. After a median follow-up of 
67 months, 3- and 5-year OS was 76.5% and 54%, 
respectively. Only 6.2% of the patients developed grade 
3 toxicity, no grade 4 toxicity was observed. Results of 
the RTOG 0618 study were reported at the ASCO 2013 
conference and 2-year OS of 84.4% was reported in 26 
patients; full publication of this study is eagerly awaited.
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To the best of our knowledge, this is all prospective 
data about stage I NSCLC patients, who were treated 
with SBRT despite being medically operable. However, 
several retrospective single-center and multi-center studies 
reported their experiences of SBRT in medically operable 
patients, who refused surgical resection (Table 1). Criteria 
and methodology of defining operable vs. inoperable 
varied between studies. Nevertheless, 3 years OS ranged 
consistently between 79% and 86% (6-10). Komiyama et al. 
have reported the largest multi-institutional study of 661 
medically operable patients treated with SBRT (10). After 
a median follow-up of 35 months, 3-year OS was 79% 
and reached 80% for the cohort of patients treated with 
sufficiently high radiation doses of ≥100 Gy BED. Two 
studies reported 5-year OS, which ranged between 51.3% 
and 69.5% (7,9). Despite the lack of randomized trials, 
there is consequently relevant and important evidence 
available.
Unknowns
In contrast to all studies discussed above, the study by Rosen 
et al. falls into the category of registry and population-
based studies, where big and mostly national databases are 
used for outcome comparisons. Rosen et al. analysed the 
National Cancer Database, which captures about 70% of 
all NSCLC cases in the United States. For 1781 so-called 
operable patients treated with SBRT the 5-year OS was 
only 29%: operable was defined as having a “Charlson-
Deyo comorbidity index of zero”. A subset of patients 
(n=235) was defined based on the coding of “Surgery of 
the primary site was not performed; it was recommended 
by the patient’s physician, but this treatment was refused 
by the patient, the patient’s family member, or the patient’s 
guardian”. In this cohort 5-year OS was better but still only 
40%. In all comparisons, OS after SBRT was significantly 
worse compared to lobectomy. Similar analyses have been 
performed using the SEER database and inconsistent results 
of SBRT compared to lobectomy have been reported (11-14).
Direct and one-by-one comparison of SBRT and surgical 
results in such registry studies is not possible and is just like 
comparing of apples and oranges. The vast majority of the 
patients treated with SBRT was inoperable and represent 
a high-risk patient population, which is obviously different 
to operable patients treated with surgery. Therefore, all 
these studies have in common that advanced and complex 
statistics is used to make surgical and SBRT patient 
cohorts as comparable as possible. However, the majority 
of the available studies including the one by Rosen et al. 
have in common that well known prognostic factors are 
unknown and therefore potential imbalances cannot be 
corrected. Especially performance status, pulmonary 
function and detailed comorbidity score are essential for 
accurate patient characterization and estimation of the 
risk of non-cancer death (15-17). The value of including 
these factors into comparative analyses between SBRT and 
lobectomy is highlighted by the study of Verstegen et al., 
where propensity matching between patients treated with 
SBRT and VATS lobectomy was based on the following 
parameters (18): cTNM stage, age, gender, Charlson 
comorbidity score, lung function and performance score. 
The comparison of 64 SBRT and 64 VATS well balanced 
patients resulted in 3-year OS of 79.6% and 76.9%, 
respectively. The true value of such registry studies remains 
unknown.
Interpretation
At this point, I will come back to the population of 
medically inoperable patients treated with SBRT. Several 
Table 1 Overall survival after SBRT for operable patients with stage I NSCLC 
Study Study type No. of patients 3-year OS (%) 5-yrar OS (%)
Chang (3) Pooled analysis of two randomized controlled trials 31 95 NA
Nagata (5) Prospective phase II 64 76.5 54.0
Uematsu (6) Retrospective 29 86.0 NA
Lagerwaard (7) Retrospective 177 84.7 51.3
Grills (8) Retrospective 56 78.0# NA
Onishi (9) Retrospective 87 NA 69.5
Komiyama (10) Retrospective 661 79.0 NA
#, 2-year overall survival rate.
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prospective phase II studies have been conducted and results 
in terms of OS are highly consistent. Despite the definition 
of medical inoperability and the risk for non-cancer risk 
most likely varied between institutions and studies, 3-year 
OS ranged between 50–60% (Table 2). Furthermore, 
very similar and consistent OS is also achieved in large 
retrospective and multi-institutional studies.
How do all these data fit into one picture? OS in 
medically operable patients treated with SBRT is about 
80% after 3 years based on prospective and retrospective 
studies discussed above. In medically inoperable patients, 
3-year OS is reduced to about 50–60%; OS varies due 
to the competing risk of death as a consequence of the 
underlying comorbidities. In the study by Rosen et al., 3-year 
OS was about 50–60% in the so-call “operable” patients 
treated with SBRT; this is very similar to survival observed 
in inoperable patient cohorts but substantially worse than 
survival observed in all studies about operable patients. In 
the lobectomy patients, 3-year OS was about 80%, which 
fits well into current literature data.
The reason for this “poor” OS after SBRT compared 
to lobectomy in the study of Rosen et al. remains largely 
unknown. What is the contribution of a potentially more 
effective lobectomy compared to SBRT? Surgical lymph 
node dissection is mostly a diagnostic and not a therapeutic 
procedure and it’s direct influence on OS is small or even 
not existing (27). About 12% of the surgical patients in 
the study of Rosen et al. had pathological positive nodes, 
of which 70% received adjuvant chemotherapy. However, 
the small benefit of adjuvant chemotherapy in a small 
proportion of the patients does also not explain the large 
difference in OS between SBRT and lobectomy (28). 
Finally, SBRT achieves local tumor control consistently in 
minimum 90% of the patients, which does not leave much 
room for improvements for surgery.
In conclusion, the most plausible explanation for the 
findings of Rosen et al. is the hypothesis, that the National 
Cancer Database did not allow for accurate identification of 
truly operable patients treated with SBRT. Patients treated 
with SBRT were most likely different to surgical patients 
in terms of their comorbidities and their consequential 
risk of non-cancer death, despite all statistical means 
trying to minimize such bias. These differences in patient 
characteristics may then explain part if not all observed 
OS differences between SBRT and lobectomy. Future 
comparative studies are urgently needed and they need 
to provide more in-depth information about the patients’ 
comorbidities and their non-cancer risk factors.
Until such data become available, surgical lobectomy 
remains the standard of care for appropriately selected 
patients. However, SBRT should be recognized as an 
alternative, which offers similar or maybe even identical OS 
compared to lobectomy. Consequently, patients need to be 
informed about available alternatives and their specific pros 
and cons—not only in terms of OS but also quality of life 
and toxicity—instead of communicating one methodology 
as the only curative option.
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Table 2 Overall survival after SBRT for medically inoperable  
patients with stage I NSCLC 
Study
No. of  
patients
3-year OS (%)
Prospective phase II studies
Nagata 2005 (19) 45 72.0
Koto 2007 (20) 31 71.7*
Baumann 2009 (21) 57 60.0
Fakiris 2009 (22) 70 42.7
Ricardi (23) 62 57.1
Timmerman (24) 55 55.8
Nagata (5) 100 59.9
Large retrospective studies 
Senthi (25) 676 Median 40.7 months
Guckenberger (26) 582 47.1; 62.2+
Grills (8) 505 60.0#
*, 11/31 medically operable; +, 164 patients treated with doses 
>106 Gy BED; #, 2 years overall survival.
2308 Guckenberger. SBRT vs. lobectomy in stage I NSCLC—currently available evidence
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(9):2305-2309jtd.amegroups.com
References
1. Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO 
Consensus Conference on Lung Cancer: early-stage non-
small-cell lung cancer consensus on diagnosis, treatment 
and follow-up. Ann Oncol 2014;25:1462-74. 
2. Palma D, Visser O, Lagerwaard FJ, et al. Impact of 
introducing stereotactic lung radiotherapy for elderly 
patients with stage I non-small-cell lung cancer: a 
population-based time-trend analysis. J Clin Oncol 
2010;28:5153-9. 
3. Chang JY, Senan S, Paul MA, et al. Stereotactic ablative 
radiotherapy versus lobectomy for operable stage I non-
small-cell lung cancer: a pooled analysis of two randomised 
trials. Lancet Oncol 2015;16:630-7.
4. Louie AV, van Werkhoven E, Chen H, et al. Patient 
reported outcomes following stereotactic ablative 
radiotherapy or surgery for stage IA non-small-cell lung 
cancer: Results from the ROSEL multicenter randomized 
trial. Radiother Oncol 2015;117:44-8. 
5. Nagata Y, Hiraoka M, Shibata T, et al. Prospective trial of 
stereotactic body radiation therapy for both operable and 
inoperable T1N0M0 non-small cell lung cancer: Japan 
Clinical Oncology Group Study JCOG0403. Int J Radiat 
Oncol Biol Phys 2015;93:989-96. 
6. Uematsu M, Shioda A, Suda A, et al. Computed 
tomography-guided frameless stereotactic radiotherapy for 
stage I non-small cell lung cancer: a 5-year experience. Int 
J Radiat Oncol Biol Phys 2001;51:666-70.
7. Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. 
Outcomes of stereotactic ablative radiotherapy in patients 
with potentially operable stage I non-small cell lung 
cancer. Int J Radiat Oncol Biol Phys 2012;83:348-53. 
8. Grills IS, Hope AJ, Guckenberger M, et al. A collaborative 
analysis of stereotactic lung radiotherapy outcomes 
for early-stage non-small-cell lung cancer using daily 
online cone-beam computed tomography image-guided 
radiotherapy. J Thorac Oncol 2012;7:1382-93. 
9. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body 
radiotherapy (SBRT) for operable stage I non-small-cell 
lung cancer: can SBRT be comparable to surgery? Int J 
Radiat Oncol Biol Phys 2011;81:1352-8. 
10. Komiyama T, Onishi H, Shioyama Y, et al. Japanese 
multicenter study of stereotactic body radiotherapy for 661 
medically operable patients with stage I non-small cell lung 
cancer. Journal of Thoracic Oncology 2015;10:S210-S1.
11. Shirvani SM, Jiang J, Chang JY, et al. Comparative 
effectiveness of 5 treatment strategies for early-stage non-
small cell lung cancer in the elderly. Int J Radiat Oncol 
Biol Phys 2012;84:1060-70. 
12. Shirvani SM, Jiang J, Chang JY, et al. Lobectomy, sublobar 
resection, and stereotactic ablative radiotherapy for early-
stage non-small cell lung cancers in the elderly. JAMA 
Surg 2014;149:1244-53. 
13. Yu JB, Soulos PR, Cramer LD, et al. Comparative 
effectiveness of surgery and radiosurgery for stage I non-
small cell lung cancer. Cancer 2015;121:2341-9. 
14. Monirul Islam KM, Shostrom V, Kessinger A, et al. 
Outcomes following surgical treatment compared to 
radiation for stage I NSCLC: a SEER database analysis. 
Lung Cancer 2013;82:90-4. 
15. Kopek N, Paludan M, Petersen J, et al. Co-morbidity 
index predicts for mortality after stereotactic body 
radiotherapy for medically inoperable early-stage non-
small cell lung cancer. Radiother Oncol 2009;93:402-7.
16. Guckenberger M, Kestin LL, Hope AJ, et al. Is there 
a lower limit of pretreatment pulmonary function for 
safe and effective stereotactic body radiotherapy for 
early-stage non-small cell lung cancer? J Thorac Oncol 
2012;7:542-51. 
17. Klement RJ, Belderbos J, Grills I, et al. Prediction of early 
death in patients with early-stage NSCLC-can we select 
patients without a potential benefit of SBRT as a curative 
treatment approach? J Thorac Oncol 2016;11:1132-9. 
18. Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage 
I-II non-small-cell lung cancer treated using either 
stereotactic ablative radiotherapy (SABR) or lobectomy by 
video-assisted thoracoscopic surgery (VATS): outcomes 
of a propensity score-matched analysis. Ann Oncol 
2013;24:1543-8.  
19. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes 
of a phase I/II study of 48 Gy of stereotactic body 
radiotherapy in 4 fractions for primary lung cancer using 
a stereotactic body frame. Int J Radiat Oncol Biol Phys 
2005;63:1427-31.
20. Koto M, Takai Y, Ogawa Y, et al. A phase II study on 
stereotactic body radiotherapy for stage I non-small cell 
lung cancer. Radiother Oncol 2007;85:429-34. 
21. Baumann P, Nyman J, Hoyer M, et al. Outcome in 
a prospective phase II trial of medically inoperable 
stage I non-small-cell lung cancer patients treated 
with stereotactic body radiotherapy. J Clin Oncol 
2009;27:3290-6. 
22. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. 
Stereotactic body radiation therapy for early-stage 
non-small-cell lung carcinoma: four-year results of a 
2309Journal of Thoracic Disease, Vol 8, No 9 September 2016
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2016;8(9):2305-2309jtd.amegroups.com
prospective phase II study. Int J Radiat Oncol Biol Phys 
2009;75:677-82.
23. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic 
body radiation therapy for early stage non-small cell 
lung cancer: results of a prospective trial. Lung Cancer 
2010;68:72-7. 
24. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body 
radiation therapy for inoperable early stage lung cancer. 
JAMA 2010;303:1070-6. 
25. Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of 
disease recurrence after stereotactic ablative radiotherapy 
for early stage non-small-cell lung cancer: a retrospective 
analysis. Lancet Oncol 2012;13:802-9.
26. Guckenberger M, Allgäuer M, Appold S, et al. Safety 
and efficacy of stereotactic body radiotherapy for stage 1 
non-small-cell lung cancer in routine clinical practice: a 
patterns-of-care and outcome analysis. J Thorac Oncol 
2013;8:1050-8.
27. Darling GE, Allen MS, Decker PA, et al. Randomized 
trial of mediastinal lymph node sampling versus complete 
lymphadenectomy during pulmonary resection in the 
patient with N0 or N1 (less than hilar) non-small cell 
carcinoma: results of the American College of Surgery 
Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 
2011;141:662-70. 
28. Burdett S, Pignon JP, Tierney J, et al. Adjuvant 
chemotherapy for resected early-stage non-small cell lung 
cancer. Cochrane Database Syst Rev 2015;(3):CD011430.
Cite this article as: Guckenberger M. SBRT versus lobectomy 
in stage I NSCLC: knowns, unknowns and its interpretation. J 
Thorac Dis 2016;8(9):2305-2309. doi: 10.21037/jtd.2016.08.59
